RO4917523 1.5 mg
Sponsors
Hoffmann-La Roche
Conditions
Fragile X SyndromeMajor Depressive Disorder
Phase 2
MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
CompletedNCT01437657
Start: 2011-10-31End: 2013-09-30Updated: 2016-11-02
A Study of RO4917523 in Patients With Fragile X Syndrome
CompletedNCT01517698
Start: 2012-05-31End: 2014-04-30Updated: 2016-07-11